The molecular mechanisms of pro-apoptotic effects of human-derived Lactobacillus reuteri ATCC PTA 6475 were investigated in this study. L. reuteri secretes factors that potentiate apoptosis in myeloid leukemia-derived cells induced by tumour necrosis factor (TNF), as indicated by intracellular esterase activity, terminal deoxynucleotidyl transferase-mediated deoxyuridine triphosphate nick end-labelling assays and poly (ADP-ribose) polymerase cleavage. L. reuteri downregulated nuclear factor-κB (NF-κB)-dependent gene products that mediate cell proliferation (Cox-2, cyclin D1) and cell survival (Bcl-2, Bcl-xL). L. reuteri suppressed TNF-induced NF-κB activation, including NF-κB-dependent reporter gene expression in a dose-and time-dependent manner. L. reuteri stabilized degradation of IκBα and inhibited nuclear translocation of p65 (RelA). Although phosphorylation of IκBα was not affected, subsequent polyubiquitination necessary for regulated IκBα degradation was abrogated by L. reuteri. In addition, L. reuteri promoted apoptosis by enhancing mitogen-activated protein kinase (MAPK) activities including c-Jun N-terminal kinase and p38 MAPK. In contrast, L. reuteri suppressed extracellular signal-regulated kinases 1/2 in TNF-activated myeloid cells. L. reuteri may regulate cell proliferation by promoting apoptosis of activated immune cells via inhibition of IκBα ubiquitination and enhancing pro-apoptotic MAPK signalling. An improved understanding of L. reuteri-mediated effects on apoptotic signalling pathways may facilitate development of future probiotics-based regimens for prevention of colorectal cancer and inflammatory bowel disease.
Lactobacillus and Bifidobacterium spp. represent sources of beneficial organisms termed probiotics, which are defined as ‘live microorganisms which when administered in adequate amounts confer health benefits to the host’ (FAO/WHO, 2001). Therapeutic effects of probiotics include alleviation of symptoms of lactose malabsorption, enhanced natural resistance to infectious diseases and chronic inflammation of the gastrointestinal tract, reduction in serum cholesterol concentration, stimulation of gastrointestinal immunity and suppression of colon cancer (Gilliland et al., 1985; Salminen et al., 1998; Perdigon et al., 2001; Rafter, 2003; Isolauri et al., 2004; Guarner et al., 2006). Probiotics are attractive candidates for novel biological therapies because beneficial bacteria may be derived from commensal microorganisms and are generally recognized as safe microbes.
Probiotic bacteria can modulate systemic inflammation, cell proliferation and apoptosis, and such properties may be useful for future immunomodulatory and cancer prevention strategies (Kato et al., 1998; Sheil et al., 2004). Anti-proliferative and pro-apoptotic effects of Lactobacillus and Bifidobacterium spp. on various cancer cell lines have been demonstrated (Fichera and Giese, 1994; Biffi et al., 1997; Kim et al., 2002). Reports also indicated that probiotic strains inhibited liver, bladder and mammary tumours in animal models, highlighting potentially systemic effects of probiotics with anti-neoplastic activities (Reddy and Rivenson, 1993; Lim et al., 2002; de Moreno de Leblanc et al., 2007). In double-blinded studies of patients fed Lactobacillus casei Shirota preparations, Aso et al. (1995) reported the suppression of bladder tumour recurrence. Lactobacillus reuteri represents a commensal-derived probiotic species with potent anti-inflammatory and anti-proliferative effects (Ma et al., 2004; Pena et al., 2005; Smits et al., 2005). L. reuteri is indigenous to humans and widely prevalent in animals (Reuter, 2001). Ma et al. (2004) reported that L. reuteri mediated its anti-inflammatory effects via inhibition of nuclear translocation of nuclear factor-κB (NF-κB) signalling in human intestinal epithelial cells. However, the precise mechanism by which L. reuteri modulates cell proliferation and apoptosis remains unknown.
Promotion of apoptosis in neoplastic cells is highly desirable as a cancer prevention strategy. Apoptosis is regulated by intracellular signalling pathways that include key factors such as NF-κB and mitogen-activated protein kinases (MAPKs) (Aggarwal, 2003). Because of the central role of NF-κB and MAPK signalling in inflammation, cell proliferation and apoptosis, we speculated that L. reuteri mediated anti-proliferative and pro-apoptotic effects by modulating NF-κB and MAPK signalling pathways. This report, which describes anti-proliferative and pro-apoptotic activities via multiple signalling pathways, represents a novel paradigm for probiotics and therapeutic microbiology.
This study investigated the effects of L. reuteri ATCC 6475 supernatant (Lr-S 6475) on tumour necrosis factor (TNF)-activated apoptosis signalling pathways in myeloid leukemia-derived cells. These studies were performed using human chronic myeloid leukemia-derived cells (KBM-5) because these cells are considered to be a well-established system for NF-κB and MAPK signalling (Ichikawa et al., 2006; Ahn et al., 2007) and express sufficient quantities of TNF receptors 1 and 2 in their baseline state.
Several methods were utilized to explore cell necrosis and apoptosis including intracellular esterase activity and plasma membrane integrity. Probiotic Lr-S 6475 enhanced TNF-induced cytotoxicity from 3% to 38% (Fig. 1A), as determined by fluorophore staining. In the absence of TNF, probiotic treatment of cells for 24 h did not diminish cell viability as determined by the 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT) (Fig. 1B) and trypan blue methods (data not shown). However, MTT assays confirmed the cytotoxic effects of Lr-S 6475 on myeloid cells in the presence of TNF (Fig. 1B). Probiotic-mediated enhancement of TNF-induced apoptosis was investigated by the terminal deoxynucleotidyl transferase (TdT)-mediated deoxyuridine triphosphate nick end-labelling (TUNEL) assays, which detect discontinuities in DNA strands as a sign of apoptosis. TNF alone was minimally effective in inducing apoptosis; however, when Lr-S 6475 and TNF were used together, the proportions of apoptotic KBM-5 cells increased from 3% to 37% as determined by TUNEL (Fig. 1C), indicating that probiotic L. reuteri 6475 upregulated TNF-induced apoptosis.
Immunoblot analyses of extracts from cells treated with Lr-S 6475 and TNF yielded evidence of activation of downstream caspases, as indicated by poly (ADP-ribose) polymerase (PARP) cleavage. In KBM-5 cells pre-treated with Lr-S 6475, the 116 kDa PARP protein was cleaved to yield a 85 kDa fragment, a hallmark of cells undergoing apoptosis (Fig. 1D). In the absence of secreted factors of probiotic L. reuteri, KBM-5 cells did not show visible evidence of PARP cleavage in response to TNF treatment. The combined results from this study showed that Lr-S 6475 enhanced TNF-induced apoptosis in human myeloid leukemia-derived cells.
Lactobacillus reuteri suppressed cell proliferation and anti-apoptotic proteins
Cyclin D1 and Cox-2 promote cell proliferation and may contribute to carcinogenesis. Cyclin D1 controls the G1-S transition and is highly expressed in a variety of tumours (Alao, 2007). Cox-2 is an enzyme that catalyses the production of PGE2 from arachidonic acid. The production of PGE2 has been linked to proliferation and metastasis of tumour cells (Jachak, 2007). TNF treatment induced the levels of Cox-2 and cyclin D1 proteins in human myeloid cells, whereas pre-treatment of cells with Lr-S 6475 suppressed TNF-induced Cox-2 and cyclin D1 proteins (Fig. 2).
The anti-apoptotic proteins, Bcl-2 and Bcl-xL, suppress apoptosis and prolong survival of neoplastic cells (Adams and Cory, 2007). Immunoblot analyses showed that TNF induced the expression of Bcl-2 and Bcl-xL in a time-dependent manner, and Lr-S 6475 pre-treatment significantly suppressed production of Bcl-2 and Bcl-xL in the presence of TNF (Fig. 2). Lr-S 6475 had no effect on protein synthesis in general as indicated by the unchanged expression of β-actin (Fig. 2). Probiotic Lr-S 6475 may promote apoptosis via suppression of proteins involved in cell proliferation and anti-apoptosis.
Because NF-κB signalling is an important regulatory pathway for cell proliferation and apoptosis, the effects of Lr-S 6475 on TNF-induced NF-κB activation were investigated. Cells were treated with Lr-S 6475 (20% v/v) for 16 h and exposed to TNF (0.1 nM) for different time intervals. Nuclear extracts were prepared and examined for evidence of NF-κB activation by DNA-binding assays. TNF activated NF-κB in a time-dependent manner in the untreated cells (Fig. 3A, left panel); however, in Lr-S 6475-treated cells, NF-κB activation was significantly inhibited (Fig. 3A, right panel). To determine the optimum time of Lr-S 6475 exposure in order to suppress NF-κB activation, cells were treated with Lr-S 6475 (20% v/v) for different time intervals prior to activation with TNF (0.1 nM). Lr-S 6475 alone did not activate NF-κB (Fig. 3B, left panel), but TNF-induced NF-κB activation was inhibited by Lr-S 6475 in a time-dependent manner (Fig. 3B, right panel). To determine the optimum dose of Lr-S 6475 required to suppress NF-κB activation, cells were treated with different concentrations of Lr-S 6475 for 16 h prior to activation with TNF (0.1 nM). Lr-S 6475 did not activate NF-κB (Fig. 3C, left panel), but pre-treatment of human myeloid cells with Lr-S 6475 inhibited TNF-induced NF-κB activation in a dose-dependent manner (Fig. 3C, right panel).
Nuclear factor-κB is composed of combinations of Rel/NF-κB. Active NF-κB heterodimers bind specific DNA sequences (Karin and Greten, 2005). When nuclear extracts from TNF-activated cells were incubated with antibodies to p50 (NF-κB1) and p65 (RelA) subunits of NF-κB, resulting band shifts indicated that TNF-activated complexes consisted of p50 or p65 subunits. The addition of excess unlabelled NF-κB (cold oligonucleotide, 100-fold) caused a complete disappearance of the band, whereas mutated oligonucleotides did not affect DNA binding (data not shown). Nuclear extracts from TNF-induced cells were incubated with Lr-S 6475 and analysed for DNA binding activity by electrophoretic mobility shift assay (EMSA). Lr-S 6475 did not interfere with the DNA binding ability of the NF-κB complex (data not shown).
As DNA binding may not correlate with effects on gene expression (Nasuhara et al., 1999), effects of probiotic mediators on TNF-induced NF-κB-dependent reporter gene transcription was evaluated. The results of secretory alkaline phosphatase (SEAP) reporter assay showed that TNF induced NF-κB-regulated reporter gene expression, and Lr-S 6475 suppressed NF-κB activation in a dose-dependent manner (Fig. 4).
Lactobacillus reuteri inhibited p65 translocation into the nucleus
The degradation of IκBα resulted in nuclear translocation of p65. Effects of Lr-S 6475 on TNF-induced nuclear translocation were examined. Data from immuno cytochemical analyses showed that TNF induced p65 nuclear translocation within 20 min in KBM-5 cells as expected, and Lr-S 6475 pre-treated cells significantly suppressed TNF-induced nuclear translocation of p65 (Fig. 5A).
Lactobacillus reuteri inhibited IκBα degradation
Nuclear translocation of NF-κB is preceded by proteolytic degradation of IκBα (Karin and Greten, 2005). To determine whether probiotics could suppress NF-κB activation by inhibition of IκBα degradation, KBM-5 cells were pre-treated with Lr-S 6475 and exposed to TNF (0.1 nM) at different time intervals. The IκBα status in the cytoplasm was analysed by immunoblot studies. TNF induced IκBα degradation in control cells (not treated with L. reuteri secreted factors) within 10 min, but Lr-S 6475 pre-treatment stabilized IκBα in the presence of TNF (Fig. 5B). These results indicate that Lr-S 6475 suppressed TNF-induced IκBα degradation.
To determine whether the inhibition of TNF-induced IκBα degradation was due to inhibition of IκBα phosphorylation, the proteasomal degradation inhibitor N-acetyl-leucylleucyl-norleucinal (ALLN) was used to block degradation of IκBα. KBM-5 cells were pre-treated with Lr-S 6475, prior to exposure to ALLN and TNF. The phosphorylation status of IκBα was evaluated by immunoblot analyses using an antibody that recognizes the serine-phosphorylated form of IκBα. TNF induced phosphorylation of IκBα within 5 min after binding to TNF receptors in myeloid cells (Fig. 5B, left panel). Lr-S 6475 pretreatment did not affect TNF-induced phosphorylation of IκBα in the presence of the proteasomal inhibitor (Fig. 5B, right panel). This result suggests that TNF binds effectively to its receptors despite the presence of probiotics. Probiotics may suppress phospho-IκBα degradation in response to TNF by interfering with downstream effectors such as ubiquitination or proteasomal degradation of IκBα. To explore this question, KBM-5 cells were pre-treated with Lr-S 6475, prior to exposure with ALLN and TNF. Results from immunoblot analyses and immunoprecipitation experiments showed that Lr-S 6475 inhibited both polyubiquitination and IκBα-specific ubiquitination respectively (Fig. 6B and C).
In view of evidence that MAPKs, such as c-Jun N-terminal kinases (JNK), p38 and extracellular signal-regulated kinases (ERK), play a critical role in cell survival and apoptosis, the effects of L. reuteri on MAPK signalling pathways were examined. Incubation of KBM-5 cells with TNF resulted in phosphorylation of JNK, p38 and ERK (Fig. 7). Pre-treatment with Lr-S 6475 enhanced JNK and p38 phosphorylation, but suppressed ERK1/2 signalling in TNF-treated KBM-5 cells (Fig. 7).
This report includes the first documentation that probiotics promote apoptosis in human myeloid cells via modulation of NF-κB and MAPK signalling. Results from this study showed that L. reuteri potentiated TNF-induced apoptosis via downregulation of NF-κB signalling and expression of gene products dependent on NF-κB activation. TNF treatment induced the expression of anti-proliferative and anti-apoptotic proteins in human myeloid cells. L. reuteri 6475 secrete factors (Lr-S 6475) that suppressed TNF-induced expression of anti-apoptotic (Bcl-2 and Bcl-xL) and cell-proliferative proteins (Cox-2 and cyclin D1). Suppression of TNF-induced Bcl-2 and Bcl-xL proteins by Lr-S 6475 correlated with the potentiation of apoptosis by TNF. Cox-2 has been implicated in carcinogenesis, and its overexpression in neoplastic cells enhanced cellular invasion, angiogenesis and antiapoptosis (Hirschowitz et al., 2002). Effects of Lr-S 6475 on the cell cycle and cell proliferation could be mediated through the downregulation of Cox-2 and cyclin D1.
Because Cox-2, cyclin D1, Bcl-2 and Bcl-xL are regulated by NF-κB, the effects of L. reuteri on NF-κB signalling were investigated. Lr-S 6475 suppressed TNF-induced NF-κB activation in a dose- and time-dependent manner. Pro-inflammatory stimuli, such as TNF, activate NF-κB through a tightly regulated pathway including phosphorylation, ubiquitination and proteolytic events (Karin and Greten, 2005). L. reuteri did not interfere with the ability of NF-κB to bind to DNA targets (data not shown). However, probiotic L. reuteri secreted factors that inhibited the ubiquitination of IκBα but did not inhibit TNF-induced IκBα phosphorylation. By suppressing ubiquitination of IκBα, L. reuteri abrogated NF-κB signalling. Polyubiquitinated IκBα is targeted for degradation by the 26S proteasome (Chen et al., 1995), facilitating the nuclear translocation of NF-κB, and sequence-specific recognition of target promoters. Lactobacillus spp. inhibited TNF-induced NF-κB activation in intestinal epithelial cells through a proteasomal degradation pathway (Petrof et al., 2004; Tien et al., 2006), suggesting that different probiotics may mediate effects on different signalling pathways. The current studies showed that the attenuation of NF-κB activation by probiotics may be mediated by secreted factors via a contact-independent mechanism.
Commensal bacteria, including Lactobacillus spp., influenced the regulatory pathways of the mammalian intestinal epithelium by directly modulating the ubiquitin–proteasome system (Kumar et al., 2007). Direct contact of a non-pathogenic Salmonella typhimurium strain with intestinal epithelial cells inhibited IκBα degradation (Neish et al., 2000). Another commensal bacterium Bacteroides thetaiotaomicron attenuated pro-inflammatory cytokine expression by inducing nuclear export of complexes formed by NF-κB and peroxisome proliferator-activated receptor-γ. The biological action of B. thetaiotaomicron is downstream of NF-κB activation (Kelly et al., 2004), whereas other commensal bacteria (including L. reuteri reported in this study) blocked NF-κB signalling at more proximal steps such as stabilization of IκBα (Neish et al., 2000; Kelly et al., 2004; Petrof et al., 2004). Suppression of NF-κB activation by probiotics in activated cells may be most effective for cancer prevention.
Recent studies reveal that JNK activation may be negatively regulated by NF-κB-mediated inhibition (De Smaele et al., 2001; Tang et al., 2001). JNK promoted TNF-induced apoptosis only in the absence of NF-κB activation (Lin and Dibling, 2002; Tang et al., 2002). L. reuteri may potentiate TNF-induced apoptosis via suppression of NF-κB activation, thereby allowing prolonged JNK activation. The p38 and JNK signalling pathways have antagonistic effects on ERK signalling (Efimova et al., 2004; Friedman and Perrimon, 2006) and can serve as additional means of regulating apoptosis via enhanced p38 and JNK phosphorylation (Xia et al., 1995). Recent findings from our laboratory also suggest that a downstream transcription factor of JNK activation, AP-1, is regulated by probiotic L. reuteri in cells treated with Toll-like receptor agonists (Y. Lin, unpubl. data).
Although direct involvement of Lr-S 6475 in MAPK signalling is not shown, L. reuteri may mediate pro-apoptotic effects via multiple signalling pathways including NF-κB and MAPKs. Therefore, L. reuteri may regulate cancer cell proliferation by altering levels of key proteins participating in apoptosis and affecting the aggregate balance of pro- and anti-apoptotic factors within TNF-stimulated cells. Similarly, de Moreno de Leblanc et al. (2007) who demonstrated that milk fermented with Lactobacillus helveticus reduced Bcl-2 expression and enhanced apoptosis in a murine cancer model. In addition, L. casei suppressed Bcl-2 gene expression in mucosal T lymphocytes of patients with Crohn's disease (Carol et al., 2006). In contrast, Lactobacillus rhamnosus GG prevented TNF-induced apoptosis in human and mouse intestinal epithelial cells by secretion of two bacterial proteins (40 and 75 kDa) (Yan and Polk, 2002; Yan et al., 2007). Different probiotics may differentially regulate cellular signalling pathways and ultimately yield different effects with respect to mammalian cell cycle regulation and cell proliferation.
In summary, these results provide clues to understanding molecular mechanisms by which L. reuteri mediates its anti-proliferative and pro-apoptotic effects in neoplastic cells. The isolation and identification of L. reuteri secreted factors (studies in progress) may also provide an improved understanding of cellular signalling associated with apoptotic signalling pathways. Further animal and human studies are needed in order to realize the therapeutic potential of commensal-derived probiotics for disorders of chronic inflammation and cancer prevention.
Recombinant human TNF was purchased from Chemicon (Temecula, CA). Iscove's Modified Dulbecco's Medium (IMDM), Dulbecco's Modified Eagle's Medium (DMEM) and fetal bovine serum were purchased from Invitrogen (Grand Island, NY). Antibodies against NF-κB subunits (p65, p50), IkBα, cyclin D1, PARP, Bcl-2 and Bcl-xL were purchased from Santa Cruz Biotechnology (Santa Cruz, CA). Anti-cyclooxygenase (Cox)-2 was purchased from BD Biosciences (San Jose, CA). Antibodies against phospho-p38, p38, phospho-JNK, JNK, phospho-ERK, ERK, Phospho-specific anti-IκBα (serine 32/36) and phospho-specific anti-p65 (serine 536) antibodies were purchased from Cell Signalling Technology (Beverly, MA). Anti-ubiquitin and β-actin antibodies were obtained from Sigma (St Louis, MO). ALLN was purchased from Calbiochem (San Diego, CA).
Human chronic myeloid leukemia-derived cells (KBM-5 cells) and human embryonic kidney cells (A293 cells) were obtained from American Type Culture Collection (Manassas, VA). KBM-5 cells were cultured in IMDM supplemented with 15% fetal bovine serum. A293 cells were cultured in DMEM supplemented with 10% fetal bovine serum.
Bacterial culture and supernatant
Lactobacillus reuteri ATCC PTA 6475 (L. reuteri 6475) was grown in a modified defined medium named LDM III (Kotarski and Savage, 1979). Overnight cultures were diluted to an OD600 of 1.0 (which equates to approximately 109 cells ml−1). Lr-S 6475 was collected by centrifugation at 4000 r.p.m. for 10 min at 4°C. The supernatants were collected by filtration through a pore size of 0.22 μm (Millipore, Bedford, MA).
The effects of Lr-S 6475 on the cytotoxic effects of TNF was determined by modified tetrazolium salt MTT uptake method as previously described (Shishodia and Aggarwal, 2004). Briefly, 5000 cells (KBM-5) were incubated with Lr-S 6475 (20% v/v) in triplicate in 96-well plates at 37°C for 48 h. MTT solution was then added to each well. After a 2 h incubation at 37°C, extraction buffer (20% SDS, 50% dimethylformamide) was added, the cells were incubated overnight at 37°C, and the optical densities were measured at 570 nm using a 96-well plate reader (Dynex Technologies, MRX Revelation, Chantilly, VA, USA). Cytotoxic effects of Lr-S 6475 were further confirmed by Live and Dead assay (Molecular Probes, Eugene, OR), which determines intracellular esterase activity and plasma membrane integrity. This assay uses calcein, a polyanionic dye, which is retained in live cells and yields green fluorescence. It also uses the ethidium monomer dye (red fluorescence), which enters cells only through damaged membranes and binds to nucleic acids but is excluded by the intact plasma membrane of live cells. Briefly, 2 × 105 cells were incubated with Lr-S 6475 (20% v/v) for 16 h and then treated with TNF (1 nM) for 24 h at 37°C. Cells were stained with the Live and Dead reagent (20% ethidium homodimer and 20% calcein-AM) and incubated at 37°C for 30 min. Cells were analysed by fluorescence microscopy (Labophot-2; Nikon, Tokyo, Japan).
The TUNEL assay
Apoptosis was detected with an ApopTag in situ detection kit from Chemicon (Temecula, CA), which employs TUNEL methodology. Briefly, cells were harvested and centrifuged at 800 g for 10 min at 4°C, and the pellet was fixed in 10% formalin overnight. After quenching of endogenous peroxidase activity, samples were incubated with a TdT enzyme mix (60 min at 37°C in a humidified chamber). Incorporated digoxigenin-labelled nucleotides were detected by using an anti-digoxigenin peroxidase-conjugated monoclonal antibody fragment. Bound peroxidase activity was detected with filtered diaminobenzidine (DAB), producing an insoluble brown-black precipitate. Slides were counterstained in hematoxylin, destained in distilled water, and dehydrated prior to mounting of coverslips with Permount. Images were examined using an Olympus BX51 microscope with an Olympus DP71 camera. The number of TUNEL-positive myeloid cells was expressed as a percentage of total DAB-positive stained cells.
poly (ADP-ribose) polymerase cleavage assay
For detection of PARP cleavage products, whole-cell extracts were prepared by subjecting Lr-S 6475-treated cells to lysis buffer (20 mM Tris, pH 7.4, 250 mM NaCl, 2 mM EDTA, pH 8.0, 0.1% Triton X-100, 0.01 μg ml−1 aprotinin, 0.005 μg ml−1 leupeptin, 0.4 mM phenylmethylsulfonyl fluoride and 4 mM NaVO4). Lysates were spun at 14 000 r.p.m. for 10 min to remove insoluble material, resolved by 7.5% SDS-PAGE, and probed with PARP antibodies.
Western blot analyses
KBM-5 cells were washed with ice-cold phosphate-buffered saline and lysed in ice-cold lysis buffer containing 1% Triton X-100, 50 mM Hepes, pH 7.4, 150 mM MgCl2, 1 mM EGTA, 100 mM NaF, 10 mM Na-pyrophosphate, 1 mM Na3VO4, 10% glycerol, 1 mM phenylmethylsulfonyl fluoride and 10 μg ml−1 aprotinin. Proteins were resolved by 10% SDS-PAGE, electroblotted to nitrocellulose membranes (Bio-Rad, Hercules, CA), and probed with various primary antibodies (as described above). After incubation with alkaline phosphatase-conjugated secondary antibodies, specific proteins (apoptosis, NF-κB and MAPKs) were detected by chemiluminescence (Applied Biosystems, Foster City, CA).
Electrophoretic mobility shift assay
To assess NF-κB activation, nuclear extracts were prepared, and EMSAs were performed as described previously (Chaturvedi et al., 2000), with the following exceptions. In brief, nuclear extracts prepared from TNF-treated cells (2 × 106 cells ml−1) were incubated with a 32P-end-labelled 45-mer double-stranded oligonucleotide (15 μg of protein with 16 fmol of DNA) from the human immunodeficiency virus long-terminal repeat 5′-TTGTTACAA GGGACTTTC CGCTG GGGACTTTC CAGGGAGGCGTGG-3′ (boldface indicates NF-κB-binding sites). After incubation for 30 min at 37°C, the DNA–protein complex was separated from free oligonucleotides in 6.6% native polyacrylamide gels. Specificity of binding of NF-κB to the DNA was also examined by competition with unlabelled oligonucleotide and binding with a double-stranded mutant oligonucleotide, 5′-TTGTTACAA CTCACTTTC CGCTG CTCACTTTC CAGGGAGGCGTGG-3′. For supershift assays, nuclear extracts prepared from TNF-treated cells were incubated with antibodies against the p50 or the p65 subunit of NF-κB for 30 min at 37°C before the complex was analysed by EMSA. The dried gels were visualized with a Phosphorimager scanner Storm 820 (Molecular Dynamics, Sunyvale, CA) and radioactive bands were quantified using Image-Quant software (GE Healthcare, Buckinghamshire, UK).
The effect of Lr-S 6475 on NF-κB-dependent reporter gene transcription induced by TNF was analysed by SEAP activity as described, with the following exceptions. To examine reporter gene expression, A293 cells (5 × 105 cells per well) were transiently transfected by the calcium phosphate method with the pNF-κB-SEAP plasmid (Invitrogen, Carlsbad, CA) and control pCMV-FLAG1 DNA plasmid for 24 h. Transfected cells were treated with Lr-S 6475 (20% v/v) for 16 h and stimulated with TNF (1 nM). The cell culture medium was harvested after 24 h of TNF treatment. The culture medium was analysed for SEAP activity according to the protocol described by the manufacturer (Clontech, Mountain View, CA) using a Victor 3 microplate reader at 570 nm (Perkin Elmer, Boston, MA).
Nuclear localization of p65 NF-κB by immunocytochemistry
Immunocytochemistry was used to examine the effect of Lr-S 6475 on the nuclear translocation of p65 as described previously (Shishodia and Aggarwal, 2004). Briefly, treated KBM-5 cells were plated on poly l-lysine-coated glass slides by centrifugation (Thermo Shandon; Cytospin 4), air-dried, and fixed with 4% paraformaldehyde after permeabilization with 0.2% Triton X-100. After being washed in PBS, the slides were blocked with 5% normal goat serum for 1 h and incubated with rabbit polyclonal anti-human p65 antibody at a 1/200 dilution. After overnight incubation at 4°C, the slides were washed, incubated with goat anti-rabbit IgG-Alexa Fluor 594 (Molecular Probes) at a 1/200 dilution for 1 h, and counterstained for nuclei with Hoechst 33342 (50 ng ml−1) for 5 min. Stained slides were analysed by fluorescence microscopy (Labophot-2; Nikon). Pictures were captured using a Photometrics Coolsnap CF colour camera (Nikon) and MetaMorph version 4.6.5 software (Universal Imaging).
KBM-5 cells (2 × 106 cells ml−1) were pre-incubated with Lr-S 6475 (20% v/v) for 16 h, incubated with ALLN (50 μg ml−1) for 30 min, and treated with TNF (1 nM) for 15 min. Cells were lysed for 30 min on ice in whole-cell extraction buffer [20 mM Hepes (pH 7.9), 50 mM NaCl, 1% Nonidet P-40, 2 mM EDTA, 0.5 mM EGTA, 2 μg ml−1 aprotinin, 2 μg ml−1 leupeptin, 0.5 mM PMSF and 2 mM sodium orthovanadate]. Lysates containing 500 μg of proteins in extraction buffer were incubated with 1 μg ml−1 antibodies for 16 h. Immune complexes were precipitated using protein A/G-Sepharose beads for 1 h at 4°C. Beads were washed with extraction buffer and resuspended in SDS sample buffer, boiled for 5 min, and size-fractionated in SDS-PAGE.
The authors acknowledge Angela Major for her technical efforts with cytology and Tiffany Morgan for assistance with manuscript preparation. The authors acknowledge Eamonn Connolly (Biogaia AB) for provision of L. reuteri strains. This work was supported by grants from the Crohn's and Colitis Foundation of America, Moran Foundation and the National Institutes of Health (RO1 DK065075, R21 AT003482). The authors also acknowledge support from the Texas Medical Center Digestive Diseases Center.